Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration

  60% confidence

• Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) therapy

  60% confidence

• This provides Mesoblast with an immediate opportunity to generate products with even greater potency for ulcerative colitis or Crohn's disease

  60% confidence

• Mayo Clinic has a financial interest in the technology through a license agreement with Mesoblast and will use any revenue to support its not-for-profit mission in patient care, education and research

  60% confidence

• Mesoblast plans to use CAR-MSC engineered to express CD19 on their surface to induce remission in Lupus Nephritis and other B cell autoimmune diseases where durable, effective and safe immunomodulation is highly desirable

  60% confidence

• This innovative genetic modification technology fits well with our strategy to extend our market leadership by creating products with even greater efficacy and new target indications

  60% confidence

• The aim of genetically engineering CAR constructs into MSCs is to substantially enhance targeted homing to inflamed tissue resulting in greater potency

  60% confidence

Cited in these Via News reports

• FDA Fast-Tracks Lung Cancer Drug as Biotech Sector Logs $430M in Deals →